NKTX / Nkarta, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Nkarta, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Employment Offer Letter between Nkarta, Inc. and Shawn Rose.

Exhibit 10.1 Nkarta, Inc. 1150 Veterans Blvd South San Francisco, CA 94080 USA June 5, 2025 Shawn Rose Via Electronic Delivery Dear Shawn, I am pleased to offer you a position with Nkarta, Inc. (the “Company”), as Chief Medical Officer and Head of R&D reporting to Paul Hastings, President. Your employment with the Company will commence on Monday, June 23, 2025 (the “Start Date”). Effective as of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights • Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 • Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., August 12, 2025 - Nkarta, Inc. (Nasdaq: NKTX),

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Exhibit 99.1 Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus SOUTH SAN FRANCISCO, Calif., June 6, 2025 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Separation and General Release Agreement between Nkarta, Inc. and Alyssa Levin.

Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (this “Agreement”) is entered into by and between Nkarta, Inc. (the “Company”) and Alyssa Levin (“you”) based on the following terms, conditions, covenants, representations, warranties, releases, and consideration. 1. Effective Date. This Agreement shall become effective on the eighth (8th) day afte

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights • Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment • Ntrust-1 expanded to include primary membranous nephropathy cohort • Lymphodepletion regimen modified across platform to inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐  Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐  Definitive Proxy Sta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights • Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases • Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 • Restructuring and workforce reduction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39370 Nkarta, Inc. (E

Policy Regarding the Recoupment of Certain Compensation Payments Adopted by the Board of Directors on September 20, 2023

EXHIBIT 97 Policy Regarding the Recoupment of Certain Compensation Payments Adopted by the Board of Directors on September 20, 2023 In the event Nkarta, Inc.

Nkarta, Inc. Insider Trading Policy.

EXHIBIT 19.1 NKARTA, INC. INSIDER TRADING POLICY (Last amended on March 14, 2025) 1. Background and Purpose of Policy Nkarta, Inc. (together with any subsidiaries that it may have from time to time, the “Company”) and all directors, officers and employees of the Company are subject to federal and state “insider trading” laws with respect to transactions involving Company securities. These laws pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Nkarta, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Sixth Amendment to Lease Agreement, dated December 20, 2024, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.

EXHIBIT 10.10(G) SIXTH AMENDMENT TO LEASE PARTIAL LEASE TERMINATION AGREEMENT This Sixth Amendment to Lease (Partial Lease Termination Agreement) (this "Sixth Amendment") is entered into as of December 20, 2024 (the “Effective Date”), by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord a

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Nkarta, Inc. and further agree to the filing of this agreement as an exhibit thereto. In ad

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ………….. Form S-8 (Form Type) ………………………………………………..……………… Nkarta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equ

As filed with the Securities and Exchange Commission on January 2, 2025

As filed with the Securities and Exchange Commission on January 2, 2025 Registration No.

NKTX / Nkarta, Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 65487U108 (CUSIP Numbe

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Nkarta, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. This

NKTX / Nkarta, Inc. / COMMODORE CAPITAL LP Passive Investment

SC 13G/A 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65487U108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

NKTX / Nkarta, Inc. / Flynn James E Passive Investment

SC 13G/A 1 e664010sc13ga-nkarta.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Nkarta, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65487U108 (CUSIP Number) September 30, 2024 (

NKTX / Nkarta, Inc. / Adage Capital Management, L.P. Passive Investment

SC 13G/A 1 p24-3044sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)*, ** Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies • Enrollment in Ntrust-2 expected to initiate by year-end 2024 • Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 • No further NKX019 dev

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Employment Offer between Nkarta, Inc. and Nadir Mahmood.

Exhibit 10.1 Nkarta, Inc. 1150 Veterans Boulevard South San Francisco, CA 94080 USA July 11, 2024 Nadir Mahmood, Ph.D. Via Electronic Delivery Dear Nadir, I am pleased to offer you a position with Nkarta, Inc. (the “Company”) as President reporting to Paul Hastings, Chief Executive Officer. Your employment with the Company will commence on July 29, 2024 (the “Start Date”). Effective as of the Star

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Nkarta, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-2 2 ff4031882ex2-nkarta.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G in respect of the Common Stock of Nkarta, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of

NKTX / Nkarta, Inc. / Boxer Capital Management, LLC Passive Investment

SC 13G/A 1 ff403188213ga1-nkarta.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 65487U108 (CUSIP Number) October 10, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis • Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 • Cash balance of $426.7 million on June

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Num

Amendment No. 3 to the Research Collaboration Agreement, dated April 3, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG.

Exhibit 10.1(A) CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK "[***]". Amendment No. 3 to the RESEARCH Collaboration Agreement This Amendment No. 3 to the

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis • Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 • Cash balance of $426.7 million on June

Amendment No. 4 to the Research Collaboration Agreement, dated May 2, 2024, by and between Nkarta, Inc. and CRISPR Therapeutics AG.

Exhibit 10.1(B) CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK "[***]". Amendment No. 4 to the RESEARCH Collaboration Agreement This Amendment No. 4 to the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) w Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Exhibit 99.1 Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President SOUTH SAN FRANCISCO, Calif., July 16, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilit

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engin

Exhibit 99.1 Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of sys

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Second Amendment to Restated Certificate of Incorporation of Nkarta, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF NKARTA, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Nkarta, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follow

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors Senior R&D leader brings extensive expertise in immunology, clinical development and translational science

Exhibit 99.1 Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors Senior R&D leader brings extensive expertise in immunology, clinical development and translational science SOUTH SAN FRANCISCO, Calif., June 13, 2024 – Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies toda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Nkarta, Inc. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) w Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights • Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 • Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments • Strong balance sheet, bolstered by recent $240.1 million offering, expected to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐  Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐  Definitive Proxy Sta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐ D

NKTX / Nkarta, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nkarta, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 65487U 108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500

NKTX / Nkarta, Inc. / Samsara BioCapital, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nkarta, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 65487U 108 (CUSIP Number) Abrar Hussain Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA 94301 (650) 285-4270 (Name, Address and Telephone

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Nkarta, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Form of Pre-Funded Warrant

Exhibit 4.1 NKARTA, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: (subject to adjustment) Warrant No. Original Issue Date: March , 2024 Nkarta, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, or its registered assigns (the “Holder”), is entitled, subj

Underwriting Agreement, dated March 25, 2024, among Nkarta, Inc., Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 21,010,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,000,031 Shares of Common Stock NKARTA, INC. Common Stock UNDERWRITING AGREEMENT March 25, 2024 Leerink Partners LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Cowen and Company, LLC 599 Lexington Avenue New Y

NKTX / Nkarta, Inc. / New Enterprise Associates 15, L.P. - NEW ENTERPRISE ASSOCIATES 15, L.P. / NKARTA, INC. -- SCHEDULE 13D/A(#2) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nkarta, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Addr

NKTX / Nkarta, Inc. / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Nkarta, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 65487U 10 8 (CUSIP Number) Victor

21,010,000 shares of Common Stock Pre-Funded Warrants to Purchase 3,000,031 shares of Common Stock

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270680 PROSPECTUS SUPPLEMENT (to Prospectus dated May 5, 2023) 21,010,000 shares of Common Stock   Pre-Funded Warrants to Purchase 3,000,031 shares of Common Stock   Nkarta, Inc. We are offering an aggregate of 21,010,000 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Nkarta, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expe

March 2024 ENGINEERING Natural Killer Cells for next generation treatment of autoimmune diseases and cancer ON DEMAND CONFIDENTIAL Exhibit 99.

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion • Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019 • Pipeline realignment focuses resources

Policy Regarding the Recoupment of Certain Compensation Payments.

EXHIBIT 97 Policy Regarding the Recoupment of Certain Compensation Payments Adopted by the Board of Directors on September 20, 2023 In the event Nkarta, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39370 Nkarta, Inc. (E

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Employment Offer Letter between Nkarta, Inc. and David Shook.

EXHIBIT 10.6(D) Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, CA 94080 USA January 15, 2020 David Shook Via Electronic Delivery Dear David, I am pleased to offer you a position with Nkarta, Inc. (the "Company"), as Medical Director, Clinical Development and initially reporting to the Chief Medical Officer. Your employment with the Company will commence on June 1, 2020 (the "Sta

Description of Capital Stock.

EXHIBIT 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Nkarta, Inc. (“us,” “our,” “we” or the “Company”) is a summary of the rights of our common stock and certain provisions of our amended and restated certificate of incorporation (the “Certificate of Incorporation”) and our amended and restated bylaws (the “Bylaws”) currently in effect. This summary does not p

NKTX / Nkarta, Inc. / LSP 6 Holding C.V. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) Bas Vaessen LSP 6 Management B.V. Johannes Vermeerplein 9 Amsterdam, Netherlands, 1071 DV +31 20 664 5500 (Name, Address and Te

NKTX / Nkarta, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - NKARTA, INC. Passive Investment

SC 13G/A 1 p24-0447sc13ga.htm NKARTA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate

Joint Filing Agreement, dated January 18, 2024, among the Reporting Persons.

Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G in respect of the Common Stock of Nkarta, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional

NKTX / Nkarta, Inc. / Boxer Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U108 (CUSIP Number) January 8, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expe

JANUARY 2024 ENGINEERING Natural Killer Cells for next generation treatment of cancer and autoimmune diseases ON DEMAND Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Nkarta, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

As filed with the Securities and Exchange Commission on January 3, 2024

As filed with the Securities and Exchange Commission on January 3, 2024 Registration No.

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ………….. Form S-8 (Form Type) ………………………………………………..……………… Nkarta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equ

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights • FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune disease • NKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease while maintaining NK-driven safety profile • New pipeline program builds on academic studies of durable, dr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

NKTX / Nkarta Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - NKARTA, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U108 (CUSIP Number) October 24, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which th

NKTX / Nkarta Inc / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NKTX / Nkarta Inc / Flynn James E Passive Investment

SC 13G 1 e619029sc13g-nkarta.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Nkarta, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65487U108 (CUSIP Number) October 17, 2023 (Date o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Nkarta, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic

Exhibit 99.1 Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-t

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET

Exhibit 99.1 Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it wil

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights • NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimen • NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings • Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the fi

Fourth Amendment to Lease, dated June 14, 2023, by and between Nkarta, Inc. and HCP BTC, LLC.

Exhibit 10.2(B) FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of the date of last signature below, by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to that certain Lease dated July 9, 2021 (the “Ori

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Nkarta, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Employment Offer Letter between Nkarta, Inc. and Alyssa Levin.

Exhibit 10.1 Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, CA 94080 USA June 29, 2023 Alyssa Levin Via Electronic Delivery Dear Alyssa, I am pleased to offer you a position with Nkarta, Inc. (the “Company”), as Chief Financial and Business Officer (“CFBO”) and reporting to Paul Hastings, Chief Executive Officer. Your employment with the Company will commence on July 1, 2023 (th

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Exhibit 99.1 Nkarta Appoints Alyssa Levin Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., July 5, 2023 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of Alyssa Levin as Chief Financial and Business Officer. “Alyssa is a results-oriented leader with substantial fin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Forward looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expe

Clinical Program Update: NKX101 for Relapsed or Refractory AML 27 June 2023 Clinical Data as of 10 Jun 2023 Exhibit 99.

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Exhibit 99.1 Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia • Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine) • In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET

Exhibit 99.1 Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., June 26, 2023 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Nkarta, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Amendment to Restated Certificate of Incorporation of Nkarta, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF NKARTA, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Nkarta, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1

Nkarta, Inc. Non-Employee Director Compensation Policy, as amended on March 22, 2023.

Exhibit 10.2 NKARTA, INC. DIRECTOR COMPENSATION POLICY (Last Amended March 22, 2023) Directors of Nkarta, Inc., a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company. The Board (or any commi

Third Amendment to Lease, dated April 25, 2023, by and between HCP BTC, LLC and Nkarta, Inc.

Exhibit 10.3 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this "Third Amendment") is made and entered into as of April 25, 2023, by and between HCP BTC, LLC, a Delaware limited company (“Landlord”), and NKARTA, INC., a Delaware corporation (“Tenant”). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated July 9, 2021 (the “Original Lease”), as amended by that ce

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 - Nkarta, Inc. (Nasdaq:

Amendment No. 2 to the Research Collaboration Agreement, dated March 8, 2023, by and between Nkarta, Inc. and CRISPR Therapeutics AG.

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK "[***]". EXECUTION VERSION Amendment No. 2 to the RESEARCH Collaboration Agreement This Amendme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, California 94080

Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, California 94080 May 3, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Nkarta, Inc. Registration Statement on Form S-3/A Filed April 24, 2023 File No. 333-270680 Request for Acceleration Dear Mr. Crawford, Pursua

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐  Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒   D

As filed with the Securities and Exchange Commission on April 24, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 24, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐  Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐  Definitive Proxy Sta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐  Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐  De

Nkarta Announces Departure of Chief Financial & Business Officer

Exhibit 99.1 Nkarta Announces Departure of Chief Financial & Business Officer • Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Nadir Mahmood, PhD,

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Form of Indenture for Subordinated Debt Securities

EX-4.7 Exhibit 4.7 NKARTA, INC. INDENTURE Dated as of , 20 [ ] Trustee Subordinated Securities TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 S

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nkarta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward Fi

Form of Indenture for Senior Debt Securities

EX-4.6 Exhibit 4.6 NKARTA, INC. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Se

Power of Attorney

S-3 1 d478111ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on March 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nkarta, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4515206 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Nkarta, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Form of non-qualified Stock Option Agreement between Nkarta, Inc. and certain of its officers and employees.

EXHIBIT 10.3(E) NKARTA, INC. 2020 PERFORMANCE INCENTIVE PLAN NOTICE OF GRANT OF STOCK OPTION Nkarta, Inc., a Delaware corporation, (the “Corporation”), pursuant to its 2020 Performance Incentive Plan, as may be amended from time to time (the “Plan”), granted on the Date of Grant set forth below (the “Award Date”) to the award recipient listed below (the “Grantee”), a nonqualified stock option (the

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 • 2022 year-end cash and cash equivalents of $354.9 million • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stag

Form of Restricted Stock Unit Agreement between Nkarta, Inc. and certain of its officers and employees.

EXHIBIT 10.3(F) NKARTA, INC. 2020 PERFORMANCE INCENTIVE PLAN NOTICE OF GRANT OF RESTRICTED STOCK UNITS Nkarta, Inc., a Delaware corporation, (the “Corporation”), pursuant to its 2020 Performance Incentive Plan, as may be amended from time to time (the “Plan”), granted on the Date of Grant set forth below (the “Award Date”) to the award recipient listed below (the “Grantee”), an award of restricted

Form of Director Option Agreement between Nkarta, Inc. and certain of its directors.

EXHIBIT 10.3(C) NKARTA, INC. 2020 PERFORMANCE INCENTIVE PLAN NOTICE OF GRANT OF STOCK OPTION Nkarta, Inc., a Delaware corporation, (the “Corporation”), pursuant to its 2020 Performance Incentive Plan, as may be amended from time to time (the “Plan”), granted on the Date of Grant set forth below (the “Award Date”) to the award recipient listed below (the “Grantee”), a nonqualified stock option (the

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39370 Nkarta, Inc. (E

NKTX / Nkarta Inc / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-nktx123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65487U108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appr

NKTX / Nkarta Inc / Samsara BioCapital, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 tm236533d2sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65487U 108 (CUSIP Number) Miran Ahmad Chief Financial Officer Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA 94

As filed with the Securities and Exchange Commission on January 9, 2023

As filed with the Securities and Exchange Commission on January 9, 2023 Registration No.

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ………….. Form S-8 (Form Type) ………………………………………………..……………… Nkarta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equ

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

Exhibit 99.1 Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer SOUTH SAN FRANCISCO, Calif., January 9, 2023 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in c

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Forward-looking statements This presentation contains forward‐looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expe

5 December 2022 NEXT GENERATION Natural Killer Cells Engineered to Beat Cancer Exhibit 99.

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Exhibit 99.1 Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma ? 7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate) ? 5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 mono

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Nkarta, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET

Exhibit 99.1 Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 2, 2022 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights ? NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022 ? NKX019 Phase 1 clinical trial recently opened dose expansion cohorts ? Next NKX019 clinical update is expected by year-end 2022 ? Next NKX101 clinical update is expected in first h

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights ? Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company?s platform for engineered CAR NK cell therapy candidates ? Additional NKX101 and NKX019 clinical data expected by year-end

Second Amendment to Lease, dated August 11, 2022, by and between HCP BTC, LLC and Nkarta, Inc.

Exhibit 10.1 SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (this "Second Amendment") is made and entered into as of the 11th of August, 2022, by and between HCP BTC, LLC, a Delaware limited company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated July 9, 2021 (the "Original Lease"), as amend

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Fifth Amendment to Lease Agreement, dated August 11, 2022, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.

Exhibit 10.2 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this "Fifth Amendment") is made and entered into as of August 11, 2022 (the ?Effective Date?), by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated May 29, 2018 (the "Orig

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

NKTX / Nkarta Inc / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U 108 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy,

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

Exhibit 99.1 Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif., May 16, 2022 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of David R. Shook, MD, as Vice President, Clinical Development. Dr. Shook is a practicing

NKTX / Nkarta Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 65487U 10 8 (CUSIP Number) Victor

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights ? Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery; MRD negativity in 2 of 3 complete responses ? Positive prelimi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Amendment No. 1 to the Research Collaboration Agreement, dated May 4, 2022, by and between Nkarta, Inc. and CRISPR Therapeutics AG.

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK "[***]". EXECUTION VERSION Amendment No. 1 to the RESEARCH Collaboration Agreement This Amendme

NKTX / Nkarta Inc / New Enterprise Associates 15, L.P. - NEW ENTERPRISE ASSOCIATES 15, L.P. / NKARTA, INC. -- SCHEDULE 13D/A(#1) Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address and T

NKTX / Nkarta Inc / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U 108 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy,

NKTX / Nkarta Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Kolchinsky (Name, Address

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Underwriting Agreement, dated April 25, 2022, among Nkarta, Inc., Cowen and Company, LLC, SVB Securities LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein.

Exhibit 1.1 13,333,334 Shares of Common Stock NKARTA, INC. Common Stock UNDERWRITING AGREEMENT April 25, 2022 Cowen and Company, LLC SVB Securities LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Evercore Group L.L.C. 5

13,333,334 shares Nkarta, Inc. Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258766 PROSPECTUS SUPPLEMENT (to Prospectus dated September 2, 2021) 13,333,334 shares Nkarta, Inc. Common Stock This is a public offering of 13,333,334 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?NKTX.? On April 25, 2022, the last reported sale price of our commo

Forward looking statements This presentation contains forward-looking statements, within the meaning of the Private Securities This presentation has been prepared by the company based on information it has obtained from Litigation Reform Act of 1995,

Exhibit 99.2 Clinical Program Update 25 April 2022 Clinical Data as of 21 April 2022 1 Forward looking statements This presentation contains forward-looking statements, within the meaning of the Private Securities This presentation has been prepared by the company based on information it has obtained from Litigation Reform Act of 1995, regarding future events and the future results of the company

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

SUBJECT TO COMPLETION, DATED APRIL 25, 2022

Table of Contents This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed.

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achi

EX-99.1 2 d219241dex991.htm EX-99.1 Exhibit 99.1 Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative NKX0

Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate

Exhibit 99.1 Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate SOUTH SAN FRANCISCO, Calif., Apr. 22, 2022 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, t

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d348646ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems

Exhibit 99.1 Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif. ? Mar. 29, 2022 ? Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tr

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

As filed with the Securities and Exchange Commission on March 17, 2022

As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39370 Nkarta, Inc. (E

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ????.. Form S-8 ??????????????????..?????? Nkarta, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share 457(c); 457(h) 1,649,36

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Nkarta, Inc. Non-Employee Director Compensation Policy, as amended on March 16, 2022.

EXHIBIT 10.5 NKARTA, INC. DIRECTOR COMPENSATION POLICY (Last Amended March 16, 2022) Directors of Nkarta, Inc., a Delaware corporation (the ?Company?), who are not employed by the Company or one of its subsidiaries (?Non-Employee Directors?) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the ?Board?) of the Company. The Board (or any commi

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights ? On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 ? 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) ? FY 2022 - NKX019,

NKTX / Nkarta Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NKTX / Nkarta Inc / Logos Global Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

NKTX / Nkarta Inc / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U 108 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Num

First Amendment to Lease, dated November 5, 2021, by and between Nkarta, Inc. and HCP BTC, LLC.

Exhibit 10.2 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into as of the date of last signature below, by and between HCP BTC, LLC, a Delaware limited company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated July 9, 2021 (the "Lease"), whereby Land

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

Exhibit 99.1 Nkarta Reports Third Quarter 2021 Financial Results and Business Update ? Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDS ? Successful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in 2022 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company deve

Fourth Amendment to Lease, dated October 19, 2021, by and between HCP Life Science REIT, Inc. and Nkarta, Inc.

Exhibit 10.1 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of October 19th, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated May 29, 2018 (the "Original Lease"), as

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

Exhibit 99.1 Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs ? First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignancies ? Initial data from the NKX019 clinical trial expected in 2022 ? Initial data from Phase 1 clinical trial evaluating NKX101 in AML and MDS expected in 1H 2022 SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 - Nka

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

$150,000,000 Nkarta, Inc. Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258766 PROSPECTUS $150,000,000 Nkarta, Inc. Common Stock We have entered into a sales agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, dated August 12, 2021, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the Sale

Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, California 94080

Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, California 94080 August 31, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Irene Paik Re: Nkarta, Inc. Registration Statement on Form S-3 Filed August 12, 2021 File No. 333-258766 Request for Acceleration Dear Ms. Paik, Pursuant to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Form of Indenture for Senior Debt Securities

Exhibit 4.6 NKARTA, INC. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE I.????DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II.???THE SECURITIES 5 Section 2.1. Issuable in Series 5 Sect

Sales Agreement, dated August 12, 2021, by and between Nkarta, Inc. and Cowen and Company, LLC

Exhibit 1.2 NKARTA, INC. COMMON STOCK SALES AGREEMENT August 12, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Nkarta, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms

Research Collaboration Agreement, dated May 5, 2021, by and between Nkarta, Inc. and CRISPR Therapeutics AG

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK "[***]". EXECUTION VERSION RESEARCH COLLABORATION AGREEMENT This RESEARCH COLLABORATION AGREEME

As filed with the Securities and Exchange Commission on August 12, 2021

Table of Contents As filed with the Securities and Exchange Commission on August 12, 2021 Registration No.

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

Exhibit 99.1 Nkarta Reports Second Quarter 2021 Financial Results and Business Progress ? Initial data from NKX101 clinical trial expected by end of 2021 ? NKX019 patient dosing expected to start in 2H 2021 ? Collaboration with CRISPR Therapeutics to develop gene-edited cell therapies ? New lease for commercial manufacturing center / headquarters to support rapid innovation and scaled production o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Form of Indenture for Subordinated Debt Securities

Exhibit 4.7 NKARTA, INC. INDENTURE Dated as of , 20 [ ] Trustee Subordinated Securities TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section

Lease, dated July 9, 2021, by and between HCP BTC, LLC and Nkarta, Inc.

Exhibit 10.1 BRITANNIA OYSTER POINT I LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION 1.Date: July 9, 2

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

Exhibit 99.1 Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters ? 88,000 square foot facility in South San Francisco will support scaled manufacturing of Nkarta?s engineered NK cell therapy candidates, and be home to company headquarters ? Planned production expansion builds upon Nkarta?s foundational manufacturing, operational and process development exp

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

First Amendment to Employment Offer Letter between the Registrant and Dr. Nadir Mahmood

Exhibit 10.3 NKARTA, INC. AMENDMENT NO. 1 TO OFFER LETTER THIS AMENDMENT NO. 1 (this ?Amendment?) is effective as of January 1, 2019, and is made to the Offer Letter of Employment, by and between Nkarta, Inc., a Delaware corporation (the ?Company?), and Nadir A. Mahmood (?Mahmood?), dated April 2, 2018 (the ?Offer Letter?). Capitalized terms used in this Amendment that are not otherwise defined he

Employment Offer Letter between the Registrant and Dr. Nadir Mahmood

Exhibit 10.2 April 2, 2018 Nadir A. Mahmood Via E-Mail Dear Mr. Mahmood: I am pleased to offer you a position with Nkarta, Inc. (the "Company"), as Senior Vice President, Corporate Development, reporting to the Chief Executive Officer of the Company. If you decide to join us, your employment would commence on a mutually agreeable starting date (the "Effective Date"). You will receive an annual bas

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

Exhibit 99.1 Nkarta Reports First Quarter 2021 Financial Results and Business Progress ? NKX019 IND received FDA clearance; NKX019 patient dosing expected to start in 2H 2021 ? Protocol amendment to ongoing NKX101 clinical trial adds a second multi-dosing regimen and a shorter waiting period between enrollment of patients ? Initial data from NKX101 clinical trial expected by end of 2021 ? CRISPR T

Nkarta, Inc. Non-Employee Director Compensation Policy, as amended March 24, 2021

Exhibit 10.1 NKARTA, INC. DIRECTOR COMPENSATION POLICY (As Amended March 24, 2021) Directors of Nkarta, Inc., a Delaware corporation (the ?Company?), who are not employed by the Company or one of its subsidiaries (?Non-Employee Directors?) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the ?Board?) of the Company. This policy is effective

Employment Offer Letter between the Registrant and Dr. Alicia Hager

Exhibit 10.4 September 30, 2020 Alicia Hager Via Electronic Delivery Dear Alicia, I am pleased to offer you a position with Nkarta, Inc. (the ?Company?) as Chief Legal Officer reporting to the Company?s Chief Executive Officer (the ?CEO?). If you decide to join us, your employment with the Company will commence on October 26, 2020 (the ?Start Date?). Effective as of the Start Date, you will receiv

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer -Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development,

Exhibit 99.1 CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer -Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities- -Companies to co-develop and co-commercialize two chimeric antigen receptor (CAR) NK cell product candida

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Exhibit 99.1 Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies ? NKX019 to be Nkarta?s second CAR NK pipeline program to enter clinical trial SOUTH SAN FRANCISCO, Calif., April 28, 2021 ? Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39370 Nkarta, Inc. (E

Third Amendment to Lease Agreement, dated January 14, 2021, by and between Nkarta, Inc. and HCP Life Science REIT, Inc.

Exhibit 10.10(D) THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this "Third Amendment") is made and entered into as of January 14, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and NKARTA, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated May 29, 2018 (the "Original Lease"), as a

Exhibit 4.3

EXHIBIT 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Nkarta, Inc. (?us,? ?our,? ?we? or the ?Company?) is a summary of the rights of our common stock and certain provisions of our amended and restated certificate of incorporation (the ?Certificate of Incorporation?) and our amended and restated bylaws (the ?Bylaws?) currently in effect. This summary does not p

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

Exhibit 99.1 Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress ? Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) ? Interim top-line data from NKX101 clinical trial expected by end of 2021 ? On

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Nkart

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numb

- S-8

As filed with the Securities and Exchange Commission on January 15, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Form of Severance Agreement

Exhibit 10.1 SEVERANCE AGREEMENT THIS SEVERANCE AGREEMENT (this “Agreement”) is made and entered into this day of 2021 (the “Effective Date”), by and between Nkarta, Inc., a Delaware corporation (the “Company”), and [] (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: A.The Executive is currently employed with the Compa

Nkarta, Inc. Non-Employee Director Compensation Policy.

Exhibit 10.6 NKARTA, INC. DIRECTOR COMPENSATION POLICY (As Amended September 17, 2020) Directors of Nkarta, Inc., a Delaware corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“Non-Employee Directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company. This policy is effect

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D‑Based NK Cell Cancer Immunotherapy NKX101 First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

Exhibit 99.2 Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D‑Based NK Cell Cancer Immunotherapy NKX101 First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) ce

Nkarta Reports Third Quarter 2020 Financial Results

Exhibit 99.1 Nkarta Reports Third Quarter 2020 Financial Results • First patient dosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromes • IND application for NKX019 expected to be filed in 1Q 2021 • Ended third quarter 2020 with $330.2 million of cash and cash equivalents, believed to be suffici

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Num

Separation and Release Agreement between Nkarta, Inc. and Matthew Plunkett, dated October 2, 2020.

Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”) is made and entered into this 2nd day of October 2020 (the “Effective Date”), by and between Nkarta, Inc., a Delaware corporation (the “Company”), and Matthew Plunkett (“Individual”). RECITALS Individual was employed by the Company, and Individual’s employment with the Company ended on October 2,

Nkarta Announces Leadership Changes Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer

Exhibit 99.1 Nkarta Announces Leadership Changes Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., October 5, 2020 - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announce

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2020 (October 2, 2020) Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Com

NKTX / Nkarta, Inc. / Logos Global Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) July 10, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Form of Director Option Agreement between Nkarta, Inc. and certain of its directors.

Exhibit 10.5 Notice of Grant of Director Stock Option and Terms and Conditions of Director Stock Option Director: [Name] Option Number: [] [Address] Plan: 2020 Plan [Address] ID: [] Effective [] (the “Award Date”), you (the “Director”) have been granted a nonqualified stock option (the “Option”) to buy [] shares1 of Common Stock of Nkarta, Inc. (the “Corporation”) at a price of $[] per share1 (the

Form of non-qualified Stock Option Agreement between Nkarta, Inc. and certain of its officers and employees.

Exhibit 10.6 Notice of Grant of Stock Option and Terms and Conditions of Stock Option Grantee: [Name] Option Number: [] [Address] Plan: 2020 Plan [Address] ID: [] Effective [] (the “Award Date”), you (the “Grantee”) have been granted a nonqualified stock option (the “Option”) to buy [] shares1 of Common Stock of Nkarta, Inc. (the “Corporation”) at a price of $[] per share1 (the “Exercise Price”).

Nkarta Reports Second Quarter 2020 Financial Results

Exhibit 99.1 Nkarta Reports Second Quarter 2020 Financial Results • Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021 • Completed construction of cGMP clinical manufacturing facility • Completed initial public offering of common stock on July 14, 2020, raising $289.8 million in gross proceeds • Cash and cash equivalents

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2020 Nkarta, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc.

Form S-8

As filed with the Securities and Exchange Commission on August 3, 2020 Registration No.

Form of Lock-Up Agreement

EX-99.3 Exhibit 3 Form of Lock-Up Agreement February 27, 2020 COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Re: NKARTA, INC. – Registration Statement on Form S-1 for Shares of Common Stock Dear Sirs and Madams: This letter agreement (“Agree

JOINT FILING AGREEMENT

EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning su

NKTX / Nkarta, Inc. / LSP 6 Holding C.V. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Nkarta, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) Bas Vaessen LSP 6 Management B.V. Johannes Vermeerplein 9 Amsterdam, Netherlands, 1071 DV +31 20 664 5500 (Name, Address and Telep

NKTX / Nkarta, Inc. / RA Capital Management, LLC - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U108 (CUSIP Number) RA Capital Mana

NKTX / Nkarta, Inc. / New Enterprise Associates 15, L.p. - NEW ENTERPRISE ASSOCIATES 15, L.P. / NKARTA, INC. -- SCHEDULE 13D Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Nkarta, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 65487U108 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A

NKTX / Nkarta, Inc. / Samsara BioCapital, L.P. - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Lock-Up Agreement, dated as of February 24, 2020, entered into by and between the Representatives and S.R. One.

EX-2 2 ex-2.htm LOCK-UP AGREEMENT GLAXOSMITHKLINE PLC SC 13D Exhibit 2 Lock-Up Agreement February 24, 2020 Cowen and Company, LLC Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Re: NKARTA, INC. – Registration Statement on Form S-1 for Shares of Common Stock Dear S

NKTX / Nkarta, Inc. / GLAXOSMITHKLINE PLC - ACQUISITION OF BENEFICIAL OWNERSHIP Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nkarta, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 65487U 10 8 (CUSIP Number) Victoria A. Whyte GlaxoSm

NKTX / Nkarta, Inc. / Novo A/S - SCHEDULE13D Activist Investment

Schedule13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Nkarta, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65487U 108 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kenned

Form of Lock-Up Agreement, dated as of February 28, 2020 between Novo Holdings A/S and the Underwriters.

EX-99.1 Exhibit 99.1 Form of Lock-Up Agreement February 28, 2020 COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Re: NKARTA, INC. – Registration Statement on Form S-1 for Shares of Common Stock Dear Sirs and Madams: This letter agreement (“Ag

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 NKARTA, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39370 47-4515206 (State or Other Jurisdiction of Incorporation) (Commission File Num

Amended and Restated Certificate of Incorporation of Nkarta, Inc.

EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF NKARTA, INC. The name of the corporation is Nkarta, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on July 13, 2015 under the corporate name Nkarta, Inc. This Restated Certificate of Incorporation of the corporation, which res

Amended and Restated Bylaws of Nkarta, Inc.

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NKARTA, INC. Adopted June 30, 2020 To be effective on July 14, 2020 TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures for Business Brought Before a Meeting 2 2.5 Ad